Literature DB >> 22358979

Long-term culture of human LAK cells.

U Testa1, E Montesoro, D Bulgarini, G Isacchi, G Mastroberardino, F Calabresi, C Peschle.   

Abstract

Entities:  

Year:  1991        PMID： 22358979     DOI： 10.1007/BF00736833

Source DB:  PubMed          Journal:  Cytotechnology        ISSN： 0920-9069            Impact factor:   2.058


× No keyword cloud information.
  9 in total

1.  Lectin-dependent and anti-CD3 induced cytotoxicity are preferentially mediated by peripheral blood cytotoxic T lymphocytes expressing Leu-7 antigen.

Authors:  J H Phillips; L L Lanier
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

2.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

3.  Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

Authors:  S E Ettinghausen; E H Lipford; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

4.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

5.  Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.

Authors:  U Testa; A Care; E Montesoro; C Fossati; G Giannella; R Masciulli; M Fagioli; D Bulgarini; D Habetswallner; G Isacchi
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

6.  Lymphokine-activated killer cells. Analysis of progenitors and effectors.

Authors:  J R Ortaldo; A Mason; R Overton
Journal:  J Exp Med       Date:  1986-10-01       Impact factor: 14.307

7.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.

Authors:  J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

8.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

9.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.